Price T Rowe Associates Inc. MD Acquires 224,859 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Price T Rowe Associates Inc. MD raised its stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 3.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 6,870,333 shares of the company's stock after purchasing an additional 224,859 shares during the period. Price T Rowe Associates Inc. MD owned 10.61% of Kymera Therapeutics worth $276,395,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Wellington Management Group LLP grew its stake in Kymera Therapeutics by 14.9% in the 4th quarter. Wellington Management Group LLP now owns 5,307,326 shares of the company's stock valued at $213,514,000 after buying an additional 688,967 shares during the last quarter. Avoro Capital Advisors LLC boosted its holdings in shares of Kymera Therapeutics by 14.4% during the fourth quarter. Avoro Capital Advisors LLC now owns 5,150,000 shares of the company's stock worth $207,184,000 after acquiring an additional 650,000 shares during the period. Vanguard Group Inc. grew its position in shares of Kymera Therapeutics by 2.8% in the fourth quarter. Vanguard Group Inc. now owns 4,887,312 shares of the company's stock valued at $196,617,000 after purchasing an additional 133,546 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Kymera Therapeutics by 5.0% during the fourth quarter. Geode Capital Management LLC now owns 1,105,487 shares of the company's stock worth $44,484,000 after purchasing an additional 52,263 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its holdings in Kymera Therapeutics by 5.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 387,187 shares of the company's stock worth $15,577,000 after purchasing an additional 20,346 shares during the last quarter.

Analysts Set New Price Targets

KYMR has been the topic of several recent research reports. HC Wainwright increased their price objective on Kymera Therapeutics from $54.00 to $60.00 and gave the stock a "buy" rating in a research report on Friday, February 28th. Citigroup started coverage on shares of Kymera Therapeutics in a research note on Thursday, March 13th. They issued a "buy" rating and a $52.00 price objective for the company. Finally, Stephens restated an "overweight" rating and set a $60.00 target price on shares of Kymera Therapeutics in a research report on Tuesday, January 21st. Three analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Kymera Therapeutics has a consensus rating of "Moderate Buy" and an average price target of $56.36.

Kymera Therapeutics Stock Up 0.2 %

Shares of KYMR traded up $0.08 during midday trading on Tuesday, hitting $33.69. The company's stock had a trading volume of 398,607 shares, compared to its average volume of 555,754. Kymera Therapeutics, Inc. has a one year low of $19.45 and a one year high of $53.27. The stock has a market capitalization of $2.19 billion, a price-to-earnings ratio of -14.40 and a beta of 2.22. The company's fifty day simple moving average is $29.80 and its two-hundred day simple moving average is $38.46.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last issued its earnings results on Thursday, February 27th. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.12). Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The business had revenue of $7.39 million for the quarter, compared to analyst estimates of $14.81 million. On average, research analysts predict that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Insider Buying and Selling

In other Kymera Therapeutics news, insider Ellen Chiniara sold 2,241 shares of the business's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total transaction of $68,238.45. Following the sale, the insider now owns 80,085 shares of the company's stock, valued at approximately $2,438,588.25. The trade was a 2.72 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Bruce N. Jacobs sold 7,035 shares of the stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total value of $214,215.75. Following the completion of the transaction, the chief financial officer now owns 201,886 shares of the company's stock, valued at $6,147,428.70. The trade was a 3.37 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 10,659 shares of company stock worth $324,567 in the last three months. 15.82% of the stock is owned by corporate insiders.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.